Samsung Biologics lifts 2026 revenue growth outlook to 20% following a strong Q3 performance, supported by increased capacity at Plant 5 and strategic expansion in the U.S. market.
Samsung Biologics demonstrated strong financial momentum in Q3 2026, achieving KRW 1,490 billion in revenue and KRW 640 billion in operating profit. The company's decision to raise its 2026 revenue growth guidance to 20% reflects confidence in its operational scaling, specifically driven by the successful ramp-up of Plant 5 and the expansion of its U.S. manufacturing footprint.
The company recorded revenue of KRW 1,490 billion.
Samsung Biologics has raised its 2026 revenue growth guidance to 20%.
Samsung Biologics reported a robust third quarter in 2026, posting KRW 1,490 billion in revenue and KRW 640 billion in operating profit. The company subsequently raised its full-year revenue growth guidance to 20%, driven by successful ramp-ups at Plant 5 and expanded U.S. manufacturing operations.
The decision was driven by strong Q3 performance, the successful ramp-up of Plant 5, and the positive contribution of its U.S. manufacturing operations.